IBR120
IBR120 is a RAD51 inhibitor. IBR120 inhibits homologous recombination (HR) repair and attenuates RAD51-DNA interaction by binding to the hydrophobic pocket of the RAD51 core domain and disrupting RAD51 multimerization. IBR120 induces apoptotic cell death and inhibits the proliferation of a broad spectrum of cancer cell lines. IBR120 in combination with anticancer agents such as EGFR inhibitors and microtubule agents produces synergistic anti-proliferative effects. IBR120 can be used in research related to breast cancer, chronic myeloid leukemia, osteosarcoma, cervical cancer, and glioblastoma.
For research use only. We do not sell to patients.
- CAS No.: 1704699-99-9
- Formula: C23H20N2O2S
- Molecular Weight:388.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF-10A | IC50 |
>30 μM
|
Cytotoxicity against normal human mammary gland epithelial MCF10A cells assessed by XTT cell viability assay after four-day treatment.
Cytotoxicity against normal human mammary gland epithelial MCF10A cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| K562 | IC50 |
3.6 μM
|
Growth inhibition activity against K562 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against K562 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MCF7 | IC50 |
3.1 μM
|
Growth inhibition activity against MCF7 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MCF7 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-231 | IC50 |
3.5 μM
|
Growth inhibition activity against MBA-MD-231 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MBA-MD-231 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-361 | IC50 |
4.5 μM
|
Growth inhibition activity against MBA-MD-361 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MBA-MD-361 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-468 | IC50 |
3.1 μM
|
Growth inhibition activity against human MBA-MD-468 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against human MBA-MD-468 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-435 | IC50 |
4.0 μM
|
Growth inhibition activity against human MBA-MD-435 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against human MBA-MD-435 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| Hs-578T | IC50 |
4.9 μM
|
Growth inhibition activity against Hs578-T cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against Hs578-T cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| T47D | IC50 |
6.3 μM
|
Growth inhibition activity against T47D cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against T47D cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| U2OS | IC50 |
4.7 μM
|
Growth inhibition activity against U2OS cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against U2OS cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| T98G | IC50 |
9.5 μM
|
Growth inhibition activity against T98G cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against T98G cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| HeLa | IC50 |
3.6 μM
|
Growth inhibition activity against HeLa cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against HeLa cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
In Vitro
IBR120 (4 days) exhibited growth inhibitory activity in MBA-MD-468 cells with an IC50 of 3.1 μM[1].
IBR120 (4 days) selectively inhibits the growth of multiple cancer cell lines (K562, MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-468, Hs578-T, T47D, U2OS, T98G, HeLa) with IC50 values of 3~5 μM, while exhibiting significantly lower toxicity to normal MCF10A cells, with IC50 > 30 μM[1].
IBR120 (10-20 µM; 24) inhibits homologous recombination repair in HeLa cells stably expressing DR-GFP in a dose-dependent manner[1].
IBR120 (4 days) significantly enhances the killing effect of various chemotherapeutic agents on cancer cells, such as Osimertinib (HY-15772), Afatinib (HY-10261), Lapatinib (HY-50898), Imatinib (HY-15463), Vemurafenib (HY-12057), Regorafenib (HY-10331), Enzalutamide (HY-70002), and Vincristine (HY-N0488A), reducing the IC50 of these anticancer agents by up to 90%[2].
IBR120 (24 h) reduced RAD51 protein levels by more than 80% in NSCLC cell lines[2].
IBR120 inhibits HR, SSA, and Alt-EJ, but not NHEJ, in U2OS cells[3].
IBR120 inhibits RAD51 foci formation in TNBC cells[3].
IBR120 (1:10 molar ratio; 30 min) disrupts RAD51 multimerization, as shown by gel filtration profiles, with a major monomer peak appearing in the presence of IBR120[1].
IBR120 eliminated the RAD51-DNA interaction in an FP-based cell-free assay[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1704699-99-9
-
Molecular Weight 388.48
-
Formula C23H20N2O2S
-
SMILES
O=S(CC1=CC=CC=C1)(N2[C@@H](C3=CNC4=CC=CC=C34)C5=CC=CC=C5C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)